Human medicines European public assessment report (EPAR): NovoEight, turoctocog alfa, Hemophilia A, Date of authorisation: 13/11/2013, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Nuwiq, simoctocog alfa, Hemophilia A, Date of authorisation: 22/07/2014, Revision: 7, Status: Authorised

Case Medical Research ◽

10.31525/cmr-128cc36 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): NovoEight, turoctocog alfa, Hemophilia A, Date of authorisation: 13/11/2013, Revision: 7, Status: Authorised

Case Medical Research ◽

10.31525/cmr-988ce1 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Kovaltry, octocog alfa, Hemophilia A, Date of authorisation: 18/02/2016, Revision: 7, Status: Authorised

Case Medical Research ◽

10.31525/cmr-babd61 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Hemophilia A, Date of authorisation: 22/11/2018, Status: Authorised

Case Medical Research ◽

10.31525/cmr-9e7b75 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Hemophilia A, Date of authorisation: 22/11/2018, Status: Authorised

Case Medical Research ◽

10.31525/cmr-9e21cc ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Kovaltry, octocog alfa, Hemophilia A, Date of authorisation: 18/02/2016, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-bb17c4 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Hemophilia A, Date of authorisation: 18/11/2015, Revision: 8, Status: Authorised

Case Medical Research ◽

10.31525/cmr-6036cb ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Hemlibra, emicizumab, Hemophilia A, Date of authorisation: 23/02/2018, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-da5a2f ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): NovoSeven, eptacog alfa (activated), Hemophilia B,Thrombasthenia,Factor VII Deficiency,Hemophilia A, Date of authorisation: 23/02/1996, Revision: 32, Status: Authorised

Case Medical Research ◽

10.31525/cmr-6ac70d ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Hemophilia B ◽

Factor Vii ◽

Assessment Report ◽

Factor Vii Deficiency ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Iblias, octocog alfa, Hemophilia A, Date of authorisation: 18/02/2016, Revision: 4, Status: Withdrawn

Case Medical Research ◽

10.31525/cmr-29b439e ◽

2020 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text